Urinary hyaluronic acid and hyaluronidase: Markers for bladder cancer detection and evaluation of grade

Journal of Urology

Volumn 163, Issue 1, 2000, Pages 348-356

  Lokeshwar, Vinata B ^a   Öbek, Can ^a   Pham, Henri T ^a   Wei, David ^a   Young, Marvin J ^a   Duncan, Robert C ^a   Soloway, Mark S ^a   Block, Norman L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Bladder cancer markers; Cancer detection; Hyaluronic acid (HA); Hyaluronidase (HAase); Metastasis

Indexed keywords

GLYCOSAMINOGLYCAN; HYALURONIC ACID; HYALURONIDASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; TRANSITIONAL CELL CARCINOMA; TUMOR VASCULARIZATION; URINALYSIS;

EID: 0344339050     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68050-0     Document Type: Article

References (58)

1. Landis, S. H., Murray, T., Bolden, S. and Wingo, P. A.: Cancel-Statistics, 1998. CA Cancer J Clin, 48: 6, 1998.
2. Heney, N. M.: Natural history of bladder cancer. Urol Clin North Am, 19: 429, 1992.
3. Soloway, M. S.: The management of superficial bladder cancer. Cancer, 45: 1856, 1980.
4. Murphy, W. M.: Diseases of the urinary bladder, urethra, ureters and renal pelvis. In: Urological Pathology. Edited by W. M. Murphy. Philadelphia: W. B. Saunders Co., pp. 34-146, 1989.
5. American Joint Committee on Cancer.: Staging of cancer at genito-urinary sites. In: Manual for Staging Cancer, Ed. 3. Philadelphia: J. B. Lippincott Co., pp. 194-5, 1988.
6. Soloway, M. S.: Invasive bladder cancer: selection of primary treatment. Semin Oncol, 17: 551, 1990.
7. Heney, N. M., Ahmed, S., Flanigan, M. J., Frable, W., Corder, M. P., Haferman, M. D. and Hawkins, I. R.: Superficial bladder cancer progression and recurrence. J Urol, 130: 1083, 1983.
8. Friedell, G. H., Soloway, M. S., Hilgar, A. G. and Farrow, G. M.: Summary of workshop on carcinoma in situ of the bladder. J Urol, 136: 1047, 1986.
9. Cutler, S. J., Heney, N. M. and Friedell, G. H.: Longitudinal study of patients with bladder cancer: Factors associated with disease recurrence and progression. In: W. B. Bladder Cancer AUA Monographs. Edited by W. B. Bonney and G. R. Prout. Baltimore: Williams and Wilkins, pp. 35-46, 1980.
10. Raghavan, D., Shipley, W., Garnick, M., Russell, P. J. and Richie, J. P.: Biology and management of bladder cancer. N Engl J Med, 322: 1129, 1990.
11. Weiner, H. G., Vooijs, G. P. and Van't Hof-Grootenboer, B.: Accuracy of urine cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol, 37:163, 1993.
12. Koss, L. G.: Errors and pitfalls in cytology of the lower urinary tract. Monogr Pathol, 39: 60, 1997.
13. Murphy, W. M.: Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol, 21: 886, 1990.
14. Lokeshwar, V. B., Obek, C., Soloway, M. S. and Block, N. L.: Tumor-associated hyaluronic acid: A new sensitive and specific urine marker for bladder cancer. Cancer Res, 57:773, 1997. (Erratum appears in Cancer Res, 58: 3191, 1998).
15. Pham, H. T., Block, N. L. and Lokeshwar, V. B.: Tumor-derived hyaluronidase: A diagnostic urine marker for high-grade bladder cancer. Cancer Res, 57: 778 1997.
16. Laurent, T. C., Fraser J. R. E.: Hyaluronan. FASEB J, 6: 2397, 1992.
17. Knudson, W., Biswas C., Li X-Q, Nemec R. E. and O'Toole, B. P.: The role and regulation of tumor associated hyaluronan. In: The Biology of Hyaluronan. Edited by J. Whelan. Ciba Foundation Symposium. New York: Wiley Chichister, 1989.
18. Auvinen, P. K., Parkkin, E. N. J., Johansson, R. T., Agren, V. M., Tammi, R. H., Eskelinen, M. J. and Kosma, V-M.: Expression of hyaluronan in benign and malignant lesions. Int J Cancer (Ped. Oncol), 74: 477, 1997.
19. Ropponen, K., Tammi, M., Parkkinen, J., Eskelinen, M., Tammi, R., Lipponen, P., Xgren, U., Alhava, E. and Kosma, V-M.: Tumor associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res, 58: 342, 1998.
20. Knudson, W.: Tumor-associated hyaluronan. Am J Pathol, 6: 1721, 1996.
21. Wang, C., Tammi, M. and Tammi, R.: Hyaluronan distribution in the normal epithelium of esophagus, stomach, and colon and their cancers. Am J Pathol, 148: 1861, 1996.
22. Hardwick, C., Hoare, K., Owens, R., Hohn, H. P., Hook, M., Moore, D., Cripps, V., Austen, L., Nance, D. M. and Turley, E. A.: Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility. J Cell Biol, 117: 1343, 1992.
23. Peach, R. J., Hollenbaugh, D., Stamenkovic, I. and Aruffo, A.: Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J Cell Biol, 122: 257, 1993.
24. Hobarth, K., Maier, U. and Marberger, M.: Topical chemoprophylaxis of superficial bladder cancer by mitomycin C and adjuvant hyaluronidase. Eur Urol, 21: 206, 1992.
25. West, D. C. and Kumar, S.: The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp Cell Res, 183: 179, 1989.
26. Lokeshwar, V. B., Lida, N. and Bourguignon, L. Y. W.: Endothelial cell adhesion molecule GP116 is a new CD44 variant (Ex14-V10) involved in mediating hyaluronic acid-induced functions. J Biol Chem, 271: 23853, 1996.
27. Roden, L., Campbell, P., Fraser, J. R. E., Laurent, T. C., Petroff, H. and Thompson, J. N.: Enzymatic pathways of hyaluronan catabolism. In: The Biology of Hyaluronan. Edited by J. Whelan. New York: Wiley Chichister, 1989.
28. Fraser, J. R. E. and Laurent, T. C.: Turnover and metabolism of hyaluronan. In: The Biology of Hyaluronan. Edited by J. Whelan. New York: Wiley Chichister, 1989.
29. Lin, Y., Mahan, K., Lathrop, W. F., Meyers, D. G. and Primakoff, P. A. A.: Hyaluronidase activity of the sperm plasma membrane protein PH-20 enables sperm to penetrate the cumulus layer surrounding the egg. J Cell Biol, 125: 1157, 1995.
30. Frost, G. I., Csoka, T. B., Wong, T. and Stern, R.: Purification, cloning and expression of human plasma hyaluronidase. Biochim Biophys Res Comm, 236: 10, 1997.
31. Kryger, J. V. and Messing, E.: Bladder cancer screening. Semin Oncol, 23: 589, 1996.
32. Messing, E. M., Young, T. B., Hunt, V. B., Newton, M. A., Bram, L. L., Vailancourt, A., Hisgen, W. J., Greenberg, E. B., Kuglitsch, M. E. and Wegenke, J. D.: Hematuria home screening: repeat testing results. J Urol, 154: 57, 1995.
33. Britton, J. P., Dowell, A. C., Whelan, P. and Harris, C. M.: A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol, 151: 788, 1992.
34. Tengblad, A.: Affinity chromatography on immobilized hvaluronate and its application to the isolation of hyaluronate binding proteins from cartilage. Biochim Biophys Acta, 578: 281, 1979.
35. Sarosdy, M. F, Hudson, M. A., Ellis, W. J., Soloway, M. S., deVere White, R., Sheinfeld, J., Jarowenko, M. V., Schellhammer, P. F., Schervish, E. W., Patel, J. V., Chodak, G. W., Lamm, D. L., Johnson, R. D., Henderson, M., Adams, G., Blumenstein, B. A., Thoelke, K. R., Pfalzgraf, R. D., Murchison, H. A. and Brunelle, S. L.: Improved detection of recurrent bladder cancer using the Bard BTA STAT Test. Urology, 50: 349, 1997.
36. Carpinito G. A., Stadler, W. M., Briggman, J. V., Chodak, G. W., Church, P. A., Lamm, D. L., Lange, P. H., Messing, E. M., Pasciak, R. M., Reservitz, G. B., Ross, R. N., Rukstalis, D. B., Sarosdy, M. F., Soloway, M. S., Thiel R. P., Vogelzang, N. and Hayden, C. L.: Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol, 156: 1280, 1996.
37. Chen, Y. T., Hayden, C. L., Marchand, K. J. and Machete, R. W.: Comparison of urine collection methods for evaluating urinary nuclear matrix protein, NMP22, as a tumor marker. J Urol, 158: 1899, 1997.
38. Sarosdy M. F., deVere White, R. W., Soloway, M. S., Sheinfeld, J., Hudson, M. A., Schellhammer, P. F., Jarowenko, M. V., Adams, G. and Blumenstein, B. A.: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol, 154: 379, 1995.
39. Lokeshwar, V. B., Lokeshwar, B. L., Pham, H. T. and Block, N. L.: Association of hyaluronidase, a matrix-degrading enzyme with prostate cancer progression. Cancer Res, 56: 651, 1996.
40. Lokeshwar, V. B., Soloway, M. S. and Block, N. L.: Secretion of bladder tumor derived hyaluronidase activity by invasive bladder tumor cell. Cancer Letts, 131: 21, 1998.
41. Akaza, H., Miyanaga, N., Tsukamoto, T., Ishikawa, S., Noguchi, R., Ohtani, M., Kawabe, K., Kubota, Y., Fujita, K., Obata, K., Hirao, Y., Kotake, T., Ohmori, H., Kumazawa, J. and Koiso, K.: Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer-NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 study group. Gan To Kagaku Raoho, 24: 829, 1997.
42. Murphy, W. M., Rivera-Ramirez, I., Medina, C. A., Wright, N. J. and Wajsman, Z.: The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms. J Urol, 158: 2102, 1997.
43. Schmetter, B. S., Habicht, K. K., Lamm, D. L., Morales, A., Bander, N. H., Grossman, H. B., Hanna, M. G. Jr., Silberman S. R. and Butman, B. T.: A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol, 158: 801, 1997.
44. The United Kingdom and Eire Bladder Tumour Antigen Study Group.: The use of the bladder-tumour associated analyte test to determine the type of cystoscopy in the follow-up of patients with bladder cancer. Br J Urol, 79: 362, 1997.
45. Kinoshita, H., Ogawa, O., Kakehi, Y., Mishina, M., Mitsumori, K., Itoh, N., Yamada H., Terachi, T. and Yoshida, O.: Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst, 89: 724, 1997.
46. Mao, L., Schoenberg, M. P., Scicchitano, M., Erozan, Y. S., Merlo, A., Schwab, D. and Sidransky, D.: Molecular detection of primary bladder cancer by microsatellite DNA. Science, 271: 659, 1996.
47. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S. C., Nichols, P. W., Skinner, D. G., Jones, P. A. and Cote, R. J.: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med, 331: 1259, 1994.
48. Cote, R. J., Dunn, M. D., Chatterjee, S. J., Stein, J. P., Shi, S. R., Tran, Q. C., Hu, S. X., Xu, H. J., Groshen, S., Taylor, C. R., Skinner, D. G. and Benedict, W. F.: Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res, 58: 1090, 1998.
49. Raitanen, M. P., Tammela, T. L., Kallioinen, M. and Isola, J.: P53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. J Urol, 157: 1250, 1997.
50. Neulander, E., Kaneti, J., Chaimovitz, C., Sion-Vardy, N. and Douvdevani, A.: Deoxyribonucleic acid ploidy and the clinical pattern of grade 2 superficial bladder cancer. J Urol, 157: 1254, 1997.
51. Miyake, H., Hara, I., Gohji, K., Yamanaka, K., Arakawa, S. and Kamidono, S.: Urinary cytology and competitive reverse transcriptase-polymerase chain reaction analysis of a specific CD44 varaint to detect and monitor bladder cancer. J Urol, 160: 2004, 1998.
52. Klein, B. A., Zemer, R., Kessler, O. J., Zimlichman, S. and Nissenkorn, I.: Cytokeratin 20: A new marker for early detection of bladder carcinoma. J Urol, 160: 1971, 1998.
53. Sarosdy, M. F.: The use of the BTA Test in the detection of persistent or recurrent transitional-cell cancer of the bladder. World J Urol, 15: 103, 1997.
54. Ellis, W. J., Blumenstein, B. A., Ishak, L. M., and Enfield, D. L.: Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The multi-center study group. Urology, 50: 882, 1997.
55. Stampfer, D. S., Carpinito, G. A., Rodriguez-Villanueva, J., Willsey, L. W., Dinney C. P., Grossman, H. B., Pritsche, H. A. and McDougal, W. S.: Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol, 159: 394, 1998.
56. Winer, H. G., Mian, C., Haitel, A., Pycha, A., Schatzl, G. and Marberger, M.: Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol, 159: 1876, 1998.
57. Schamhart, D. H., de Reijke, T.: M., van der Poel, H. G., de Boer, E. C., Kurth, K., and Schalken, J. A.: The Bard BTA test: its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer. Eur Urol, 34: 99, 1998.
58. Johnston, B., Morales, A., Emerson, L. and Lundie, M.: Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol, 158: 2098, 1997.